Key Points
- CRO Marcus Jewell sold 12,658 shares of Cellebrite DI on May 18 at an average price of $12.77, for proceeds of about $161,643. After the sale, he still held 440,101 shares.
- The sale reduced Jewell’s ownership by 2.8%, and it followed a smaller sale of 383 shares earlier in the month.
- Analyst sentiment remains generally positive, with a Moderate Buy consensus and an average price target of $21.75, even though some firms recently trimmed targets or upgraded the stock to Hold.
Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CRO Marcus Jewell sold 12,658 shares of the company's stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares of the company's stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Marcus Jewell also recently made the following trade(s):
- On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The stock was sold at an average price of $13.01, for a total value of $4,982.83.
Cellebrite DI Stock Performance
Shares of NASDAQ:CLBT opened at $13.46 on Wednesday. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The stock has a fifty day moving average of $13.47 and a 200-day moving average of $15.45. The company has a market capitalization of $3.36 billion, a PE ratio of 48.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.15.
Analyst Ratings Changes
A number of analysts have recently issued reports on CLBT shares. Weiss Ratings upgraded Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 15th. Finally, Wall Street Zen raised shares of Cellebrite DI from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.75.
View Our Latest Stock Analysis on CLBT
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voss Capital LP lifted its stake in Cellebrite DI by 18.9% during the fourth quarter. Voss Capital LP now owns 8,050,000 shares of the company's stock worth $145,142,000 after purchasing an additional 1,277,300 shares during the period. Pertento Partners LLP increased its holdings in shares of Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company's stock worth $107,447,000 after buying an additional 1,311,109 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Cellebrite DI by 0.8% during the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company's stock worth $101,026,000 after buying an additional 43,041 shares in the last quarter. Granahan Investment Management LLC increased its holdings in shares of Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company's stock worth $55,118,000 after buying an additional 427,719 shares in the last quarter. Finally, Cooper Creek Partners Management LLC acquired a new stake in shares of Cellebrite DI during the third quarter worth approximately $55,999,000. Institutional investors own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
